- $352.54m
- $363.38m
Brief: Cytodyn In Discussions With U.S. FDA, MHRA And Health Canada After Unblinding Its CD12 Trial Data For Severe-To-Critically Ill Covid-19 Patients
Brief: FDA Resumes E-IND Approval For Severe-To-Critical Covid-19 Patients Use Of Vyrologix Following Full Enrollment In Cytodyn's Phase 3 Trial
Brief: Cytodyn Completes Enrollment For Phase 3 Registrational Trial For 390 Patients With Severe-To-Critical Covid-19
Brief: Cytodyn Reaches Enrollment Target Of 293 Patients For 2nd Interim Analysis Of Phase 3 COVID-19 Trial
Brief: CytoDyn Files Protocol With U.S. FDA For Phase 2 Clinical Trial For Covid-19 Patients With Long-Hauler Symptoms
Brief: Cytodyn Receives Positive Dsmc Recommendation After Interim Analysis For Leronlimab Phase 2B/3 Covid-19 Registrational Trial
Brief: Cytodyn Appoints Chiral Pharma To Secure Leronlimab For Local FDA Approval In Philippines
Brief: U.K. MHRA Grants Meeting To Cytodyn To Discuss Fast Track Approval Of Leronlimab For COVID-19
Brief: Cytodyn Says Will Attempt To Duplicate Berlin And London Patients’ HIV Cure
Brief: Cytodyn Submits Top-Line Report From Phase 2 Covid-19 Trial To FDA And Requests Emergency Use Approval
Brief: Cytodyn Announces Clinically Significant Top-Line Results From Phase 2 Trial In Mild-To-Moderate Covid-19 Patients
Brief: Cytodyn Seeks UK Approval Of Leronlimab For HIV And Covid-19
Brief: Cytodyn Receives Positive DSMC Recommendation For Leronlimab Phase 3 Covid-19 Trial With No Safety Concerns
Brief: Impressive Results From Cytodyn’S Phase 2 Covid-19 Trial
Brief: Cytodyn Files Application With NASDAQ For Uplist
Brief: Cytodyn Got Refusal To File Letter From FDA For BLA For Leronlimab As A Combination Therapy With Haart For Highly Treatment Experienced HIV Patients
Brief: Cytodyn Announces Agreement with American Regent for Supply of Leronlimab for Treatment of COVID-19 in the U.S.
Brief: Cytodyn Announces Execution Of Exclusive Agreement With American Regent For Distribution And Supply Of Leronlimab For Treatment Of Covid-19 In United States
Brief: Cytodyn Reached Its Enrollment Target For Phase 2 COVID-19 Trial For Mild To Moderate Indication